Aberrant splicing and drug resistance in AML
Open accessAbstract
The advent of next-generation sequencing technologies has unveiled a new window into the heterogeneity of acute myeloid leukemia (AML). In particular, recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events have been recognized as a prominent component of this disease. This review will focus on how these factors influence drug resistance through altered splicing of tumor suppressor and oncogenes and dysregulation of the apoptotic signaling network. A better understanding of these factors in disease progression is necessary to design appropriate therapeutic strategies recognizing specific alternatively spliced or mutated oncogenic targets.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
AML prominently features recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events.
“Particularly in acute myeloid leukemia (AML), a prominent component of the disease is recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events (14)(15)(16)(17).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,354 · see citing works
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,348 · see citing works
Mitochondria and cell death: outer membrane permeabilization and beyond
Tait, S. W. G., & Green, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2952 · Cited by 2,593 · see citing works
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312 · see citing works
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029 · see citing works
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993 · see citing works
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991 · see citing works
Krueger, A., Schmitz, I., Baumann, S., Krammer, P. H., & Kirchhoff, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101780200 · Cited by 565 · see citing works
Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557 · see citing works
Malcovati, L., Papaemmanuil, E., Bowen, D., Boultwood, J., Porta, M. G. D., Pascutto, C., Travaglino, E., Groves, M. J., Godfrey, A. L., Ambaglio, I., et al. (2011) · Blood · doi:10.1182/blood-2011-09-377275 · Cited by 496 · see citing works
BH3-only proteins in apoptosis and beyond: an overview
Lomonosova, E. E., & Chinnadurai, G. (2008) · Oncogene · doi:10.1038/onc.2009.39 · Cited by 459 · see citing works
Anczuków, O., Rosenberg, A. Z., Akerman, M., Das, S., Zhan, L., Karni, R., Muthuswamy, S. K., & Krainer, A. R. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2207 · Cited by 441 · see citing works
Survival for older patients with acute myeloid leukemia: a population-based study
Oran, B., & Weisdorf, D. J. (2012) · Haematologica · doi:10.3324/haematol.2012.066100 · Cited by 423 · see citing works
Thol, F. R., Kade, S., Schlarmann, C., Löffeld, P., Morgan, M. A., Krauter, J., Włodarski, M. W., Kölking, B., Wichmann, M., Görlich, K., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399337 · Cited by 420 · see citing works
The spliceosome as a target of novel antitumour drugs
Bonnal, S., Vigevani, L., & Valcárcel, J. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3823 · Cited by 403 · see citing works
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
Makishima, H., Visconte, V., Sakaguchi, H., Jankowska, A. M., Kar, S. A., Jerez, A., Przychodzen, B. P., Bupathi, M., Guinta, K. M., Afable, M. G., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399774 · Cited by 368 · see citing works
Vo, T.-T. T., Ryan, J. A., Carrasco, R. D., Neuberg, D. S., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. G. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348 · see citing works
Bcl-2–family proteins and hematologic malignancies: history and future prospects
Reed, J. C. (2008) · Blood · doi:10.1182/blood-2007-09-078162 · Cited by 346 · see citing works
An Alternative Splicing Network Links Cell-Cycle Control to Apoptosis
Moore, M. J., Wang, Q., Kennedy, C. J., & Silver, P. A. (2010) · Cell · doi:10.1016/j.cell.2010.07.019 · Cited by 316 · see citing works
Misregulation of Pre-mRNA Alternative Splicing in Cancer
Zhang, J., & Manley, J. L. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0253 · Cited by 306 · see citing works
Marani, M., Tenev, T., Hancock, D. C., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3577-3589.2002 · Cited by 287 · see citing works
U2AF1 mutations alter splice site recognition in hematological malignanciesPreprint
Ilagan, J. O., Ramakrishnan, A., Hayes, B. J., Murphy, M. E., Zebari, A. S., Bradley, P. H., & Bradley, R. K. (2014) · Genome Research · doi:10.1101/gr.181016.114 · Cited by 285 · see citing works
c-FLIP, a master anti-apoptotic regulator.
Safa, A. R. (2012) · PubMed · Cited by 272 · see citing works
Wang, Y., Chen, D., Qian, H., Tsai, Y., Shao, S., Liu, Q., Dominguez, D., & Wang, Z. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.010 · Cited by 224 · see citing works
Dolatshad, H., Pellagatti, A., Fernández‐Mercado, M., Yip, B. H., Malcovati, L., Attwood, M., Przychodzen, B. P., Sahgal, N., Kanapin, A. A., Lockstone, H. E., et al. (2014) · Leukemia · doi:10.1038/leu.2014.331 · Cited by 194 · see citing works
Proapoptotic BID is required for myeloid homeostasis and tumor suppression.Preprint
Zinkel, S. S., Ong, C., Ferguson, D., Iwasaki, H., Akashi, K., Bronson, R., Kutok, J., Alt, F., & Korsmeyer, S. (2003) · Genes & Development · doi:10.1101/gad.1045603 · Cited by 183 · see citing works
Zhou, J., Bi, C., Janakakumara, J. V., Liu, S.-C., Chng, W. J., Tay, K.-G., Poon, L.-F., Xie, Z., Palaniyandi, S., Yu, H., et al. (2009) · Blood · doi:10.1182/blood-2008-05-156422 · Cited by 167 · see citing works
Self-citationTargeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy
Safa, A. R., & Pollok, K. E. (2011) · Cancers · doi:10.3390/cancers3021639 · Cited by 166 · see citing works
The Dark Side of E2F1: In Transit beyond Apoptosis
Engelmann, D., & Pützer, B. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2575 · Cited by 160 · see citing works
Akgül, C., MOULDING, D. A., & Edwards, S. W. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4001-7 · Cited by 147 · see citing works
Ohgami, R. S., Ma, L., Merker, J. D., Gotlib, J. R., Schrijver, I., Zehnder, J. L., & Arber, D. A. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.160 · Cited by 139 · see citing works
IAP proteins as targets for drug development in oncology
Dubrez, L., Berthelet, J., & Glorian, V. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s33375 · Cited by 133 · see citing works
Shultz, J. C., Goehe, R. W., Wijesinghe, D. S., Murudkar, C. S., Hawkins, A. J., Shay, J. W., Minna, J. D., & Chalfant, C. E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1545 · Cited by 132 · see citing works
mTORC1 is essential for leukemia propagation but not stem cell self-renewal
Hoshii, T., Tadokoro, Y., Naka, K., Ooshio, T., Muraguchi, T., Sugiyama, N., Soga, T., Araki, K., Yamamura, K., & Hirao, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62279 · Cited by 130 · see citing works
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Ramos, N. R., Mo, C. C., Karp, J. E., & Hourigan, C. S. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040665 · Cited by 127 · see citing works
The splicing-factor oncoprotein SF2/ASF activates mTORC1
Karni, R., Hippo, Y., Lowe, S. W., & Krainer, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801376105 · Cited by 124 · see citing works
Abrams, M. T., Robertson, N. M., Yoon, K., & Wickstrom, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411767200 · Cited by 122 · see citing works
AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1
Nishida, S., Hosen, N., Shirakata, T., Kanato, K., Yanagihara, M., Nakatsuka, S., Hoshida, Y., Nakazawa, T., Harada, Y., Tatsumi, N., et al. (2005) · Blood · doi:10.1182/blood-2005-04-1656 · Cited by 118 · see citing works
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML
Weisberg, E., Barrett, R., Liu, Q., Stone, R. M., Gray, N. S., & Griffin, J. D. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.04.001 · Cited by 117 · see citing works
Adamia, S., Haibe-Kains, B., Pilarski, P. M., Bar-Natan, M., Pevzner, S., Avet-Loiseau, H., Lode, L., Verselis, S., Fox, E. A., Burke, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0956 · Cited by 106 · see citing works
Regulation of mitochondrial Smac/DIABLO-selective release by survivin
Ceballos‐Cancino, G., Espinosa, M., Maldonado, V., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210560 · Cited by 105 · see citing works
Merdzhanova, G., Edmond, V., Seranno, S. D., Broeck, A. V. D., Corcos, L., Brambilla, C., Brambilla, E. M., Gazzéri, S., & Eymin, B. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.135 · Cited by 103 · see citing works
Komeno, Y., Huang, Y.-J., Qiu, J., Lin, L., Xu, Y., Zhou, Y., Chen, L., Monterroza, D. D., Li, H., DeKelver, R. C., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00202-15 · Cited by 100 · see citing works
Webb, T. R., Joyner, A. S., & Potter, P. M. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.013 · Cited by 98 · see citing works
The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Larsson, C. A., Cote, G. J., & Quintás‐Cardama, A. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0695 · Cited by 94 · see citing works
Survivin Monomer Plays an Essential Role in Apoptosis Regulation
Pavlyukov, M. S., Антипова, Н. В., Balashova, M. V., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237586 · Cited by 92 · see citing works
hnRNP U Enhances Caspase-9 Splicing and Is Modulated by AKT-dependent Phosphorylation of hnRNP L
Vu, N., Park, M. A., Shultz, J. C., Goehe, R. W., Hoeferlin, L. A., Shultz, M. D., Smith, S. A., Lynch, K. W., & Chalfant, C. E. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.443333 · Cited by 92 · see citing works
Tejedor, J. R., Papasaikas, P., & Valcárcel, J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.10.029 · Cited by 91 · see citing works
Himeji, D., Horiuchi, T., Tsukamoto, H., Hayashi, K., Watanabe, T., & Harada, M. (2002) · Blood · doi:10.1182/blood.v99.11.4070 · Cited by 89 · see citing works
Weber, A., Paschen, S. A., Heger, K., Wilfling, F., Frankenberg, T., Bauerschmitt, H., Seiffert, B. M., Kirschnek, S., Wagner, H., & Häcker, G. A. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200610148 · Cited by 86 · see citing works
Fu, J., Jin, Y. H., & Arend, L. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308036200 · Cited by 81 · see citing works
Stasi, R., Poeta, G. D., Venditti, A., et al. (1994) · Blood · doi:10.1182/blood.v83.6.1619.1619 · Cited by 81 · see citing works
U2AF1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
Qian, J., Yao, D., Lin, J., Qian, W., Wang, C.-Z., Chai, H., Yang, J. C., Li, Y., Deng, Z., Ma, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045760 · Cited by 78 · see citing works
Chemical Perturbation of Mcl-1 Pre-mRNA Splicing to Induce Apoptosis in Cancer Cells
Gao, Y., & Koide, K. (2013) · ACS Chemical Biology · doi:10.1021/cb300602j · Cited by 78 · see citing works
Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)
Bose, P., & Grant, S. (2013) · Leukemia Research Reports · doi:10.1016/j.lrr.2012.11.006 · Cited by 72 · see citing works
Functional roles of protein splicing factors
Chen, H.-C., & Cheng, S.-C. (2012) · Bioscience Reports · doi:10.1042/bsr20120007 · Cited by 67 · see citing works
Huang, T., Myklebust, L. M., Kjarland, E., Gjertsen, B. T., Pendino, F., Bruserud, Ø., Døskeland, S. O., & Lillehaug, J. R. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-31 · Cited by 63 · see citing works
Goncharenko-Khaider, N., Lane, D. P., Matte, I., et al. (2010) · Oncogene · doi:10.1038/onc.2010.288 · Cited by 63 · see citing works
Mohr, A., Zwacka, R. M., Jármy, G., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208432 · Cited by 59 · see citing works
Wagner, M., Schmelz, K., Wuchter, C., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21995 · Cited by 56 · see citing works
Adamia, S., Bar‐Natan, M., Haibe‐Kains, B., Pilarski, P. M., Bach, C., Pevzner, S. J., Calimeri, T., Avet‐Loiseau, H., Lodé, L., Verselis, S. J., et al. (2014) · Blood · doi:10.1182/blood-2013-02-481507 · Cited by 52 · see citing works
Prognostic and therapeutic relevance of c‐ FLIP in acute myeloid leukaemia
McLornan, D. P., Hay, J., McLaughlin, K. M., Holohan, C., Burnett, A. K., Hills, R. K., Johnston, P. G., Mills, K., McMullin, M. F., & Longley, D. B. (2012) · British Journal of Haematology · doi:10.1111/bjh.12108 · Cited by 48 · see citing works
Dolatshad, H., Pellagatti, A., Fernández‐Mercado, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.178 · Cited by 48 · see citing works
Clinico-pathologic relevance of Survivin splice variant expression in cancer
de Necochea-Campion, R., Chen, C.-S., Mirshahidi, S., Howard, F. D., & Wall, N. R. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.06.007 · Cited by 47 · see citing works
Self-citationSplice factor mutations and alternative splicing as drivers of hematopoietic malignancy
Hahn, C. N., Venugopal, P., Scott, H. S., & Hiwase, D. (2014) · Immunological Reviews · doi:10.1111/imr.12241 · Cited by 46 · see citing works
Comparison of Splicing Factor 3b Inhibitors in Human Cells
Gao, Y., Vogt, A., Forsyth, C. J., et al. (2012) · ChemBioChem · doi:10.1002/cbic.201200558 · Cited by 45 · see citing works
Three Novel Bid Proteins Generated by Alternative Splicing of the Human Bid Gene
Renshaw, S. A., Dempsey, C. E., Barnes, F. A., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309769200 · Cited by 42 · see citing works
Perry, W. L., Shepard, R. L., Sampath, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-3675 · Cited by 42 · see citing works
Brown‐Bryan, T. A., Leoh, L. S., Ganapathy, V., Pacheco, F. J., Mediavilla-Varela, M., Filippova, M., Linkhart, T. A., Gijsbers, R., Debyser, Z., & Casiano, C. A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0125 · Cited by 40 · see citing works
Challenges in Treating Older Patients with Acute Myeloid Leukemia
Lagadinou, E. D., Nicholas, Z. C., & Spyridonidis, A. (2010) · Journal of Oncology · doi:10.1155/2010/943823 · Cited by 39 · see citing works
The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes
Boultwood, J., Dolatshad, H., Varanasi, S. S., Yip, B. H., & Pellagatti, A. (2013) · Advances in Biological Regulation · doi:10.1016/j.jbior.2013.09.005 · Cited by 36 · see citing works
Moore, A. S., Alonzo, T. A., Gerbing, R. B., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24822 · Cited by 30 · see citing works
Lim, K., Yeo, W. S., & Chow, V. T. K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11660 · Cited by 28 · see citing works
Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)
Mohamed, A. M., Balsat, M., Thénoz, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3898 · Cited by 27 · see citing works
AML sensitivity to YM155 is modulated through AKT and Mcl-1
de Necochea-Campion, R., Osterman, C. J. D., Hsu, H.-W., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.034 · Cited by 26 · see citing works
Ishizawa, J., Kojima, K., McQueen, T. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138377 · Cited by 26 · see citing works
Obiol‐Pardo, C., Granadino‐Roldán, J. M., & Rubio, J. (2008) · Journal of Molecular Recognition · doi:10.1002/jmr.887 · Cited by 25 · see citing works
Enhancement of cellular radiation sensitivity through degradation of Chk1 by the XIAP-XAF1 complex
Kim, K. S., Heo, J., Choi, K. J., & Bae, S. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.962305 · Cited by 24 · see citing works
Andersson, C., Li, X., Lorenz, F., et al. (2012) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e318257ddb9 · Cited by 23 · see citing works
Role of IG20 Splice Variants in TRAIL Resistance
Prabhakar, B. S., Mulherkar, N., & Prasad, K. V. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0493 · Cited by 23 · see citing works
Regulation of chemoresistance via alternative messenger RNA splicing
Eblen, S. T. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.041 · Cited by 22 · see citing works
Karimi, M., Nilsson, C. C., Dimitriou, M., Jansson, M., Matsson, H., Unneberg, P., Lehmann, S., Kere, J., & Hellström‐Lindberg, E. (2015) · Haematologica · doi:10.3324/haematol.2014.118034 · Cited by 18 · see citing works
Tse, M., Cho, C. K., Wong, W.-F., et al. (2012) · Protein Science · doi:10.1002/pro.2126 · Cited by 17 · see citing works
Stoleriu, M. G., Steger, V., Mustafi, M., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu087 · Cited by 17 · see citing works
Many pathways to apoptosis: E2F1 regulates splicing of apoptotic genes
Korotayev, K., & Ginsberg, D. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.155 · Cited by 15 · see citing works
Expression of different functional isoforms in haematopoiesis
Grech, G., Pollacco, J., Portelli, M., Sacco, K. A., Baldacchino, S., Grixti, J. M., & Saliba, C. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1477-7 · Cited by 14 · see citing works
Identification and characterization of two splicing variants of human Noxa.
Wang, Z., & Sun, Y. (2008) · PubMed · Cited by 13 · see citing works
Discovering Transcription and Splicing Networks in Myelodysplastic Syndromes
Wang, H., Wen, J., Chang, C.-C., & Zhou, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079118 · Cited by 13 · see citing works
Notarbartolo, M., Cervello, M., Dusonchet, L., et al. (2002) · Leukemia Research · doi:10.1016/s0145-2126(02)00016-4 · Cited by 12 · see citing works
Hatakeyama, K., Yamakawa, Y., Fukuda, Y., Ohshima, K., Wakabayashi‐Nakao, K., Sakura, N., Tanizawa, Y., Kinugasa, Y., Yamaguchi, K., Terashima, M., et al. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0426-3 · Cited by 11 · see citing works
Aratake, K., Kamachi, M., Iwanaga, N., et al. (2005) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2005.05.004 · Cited by 10 · see citing works
How mRNA is misspliced in acute myelogenous leukemia (AML)?
Mohamed, A. M., Thénoz, M., Solly, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2304 · Cited by 10 · see citing works
Ju, W., Huang, G., Luo, X., et al. (2014) · Medical Oncology · doi:10.1007/s12032-014-0273-4 · Cited by 8 · see citing works
Death Receptor Expression on Blasts in AML Is Associated with Unfavorable Prognosis.
Schmohl, J. U., Nuebling, T., Wild, J. S., et al. (2015) · PubMed · Cited by 8 · see citing works
Spliceosome Inhibitor Meayamycin B As a Novel Potential Chemotherapeutic Agent in ALL and AML
Wojtuszkiewicz, A., Assaraf, Y. G., Jansen, G., et al. (2014) · Blood · doi:10.1182/blood.v124.21.924.924 · Cited by 3 · see citing works
Paroxysmal nocturnal hemoglobinuria: An acquired genetic disease
Nishimura, J., Murakami, Y., & Kinoshita, T. (1999) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199911)62:3
Flagged first, then by citations
Cited by
Sorted by citations
Alternative Splicing of NOX4 in the Failing Human Heart
Varga, Z. V., Pipicz, M., Baán, J. A., Baranyai, T., Koncsos, G., Leszek, P., Kuśmierczyk, M., Sánchez-Cabo, F., García-Pavía, P., Brenner, G. J., et al. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00935 · Cited by 43 · see citing works
Mäkelä, E., Pavic, K., Varila, T., Salmenniemi, U., Löyttyniemi, E., Nagelli, S. G., Ammunét, T., Kähäri, V.-M., Clark, R. E., Elo, L. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3679 · Cited by 18 · see citing works
- Authors
- de Necochea-Campion, R., Shouse, G. P., Zhou, Q., Mirshahidi, S., & Chen, C.-S.
- Affiliations
- Loma Linda University Medical Center (US)
- Corresponding author
- Chen, Chien-Shing
- Venue
- Journal of Hematology & Oncology
- Published
- 2016-09-10
- Volume
- 9
- Issue
- 1
- Pages
- 85-85
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC5018179
- OpenAlex
- W2514986598
- Cited by
- 66
- References
- 96
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 10 · 2022: 10 · 2021: 8 · 2020: 9 · 2019: 8 · 2018: 4 · 2017: 7
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Loma Linda University
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, aberrant splicing, spliceosome mutations, drug resistance, alternative splicing, tumor suppressor, oncogenes, apoptosis signaling, leukemia heterogeneity, therapeutic target
- MeSH terms
- Humans, Oncogenes, Leukemia, Myeloid, Acute, Genes, Tumor Suppressor, Apoptosis, Alternative Splicing, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
